APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Gene-based Advanced Therapy Medical Product

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gene-based Advanced Therapy Medical Product Market Outlook and Growth Opportunities 2026

Report ID 17399457042 January 2026196 pages

Choose your research edition.

Industry ResearchGene-based Advanced Therapy Medical Product Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene-based Advanced Therapy Medical Product Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Gene-based Advanced Therapy Medical Product Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene-based Advanced Therapy Medical Product Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene-based Advanced Therapy Medical Product Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Gene-based Advanced Therapy Medical Product market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gene-based Advanced Therapy Medical Product is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gene-based Advanced Therapy Medical Product is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gene-based Advanced Therapy Medical Product is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gene-based Advanced Therapy Medical Product market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gene-based Advanced Therapy Medical Product market include Novartis, Amgen, Sunway Biotech, Spark Therapeutics, SIBIONO, Sarepta Therapeutics, Orchard Therapeutics, Human Stem Cells Institute and Gilead Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Gene-based Advanced Therapy Medical Product market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gene-based Advanced Therapy Medical Product and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gene-based Advanced Therapy Medical Product revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Gene-based Advanced Therapy Medical Product market.

Gene-based Advanced Therapy Medical Product Segment by Company

Novartis

Amgen

Sunway Biotech

Spark Therapeutics

SIBIONO

Sarepta Therapeutics

Orchard Therapeutics

Human Stem Cells Institute

Gilead Sciences

bluebird bio

Biogen

AnGes

Alnylam Pharmaceuticals

Akcea Therapeutics

Gene-based Advanced Therapy Medical Product Segment by Type

Viral Gene Delivery System

Non-viral Gene Delivery System

Gene-based Advanced Therapy Medical Product Segment by Application

Neurological Diseases

Cancer

Other

Gene-based Advanced Therapy Medical Product Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Gene-based Advanced Therapy Medical Product status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Gene-based Advanced Therapy Medical Product key companies, revenue, market share, and recent developments.

3. To split the Gene-based Advanced Therapy Medical Product breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Gene-based Advanced Therapy Medical Product market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gene-based Advanced Therapy Medical Product significant trends, drivers, influence factors in global and regions.

6. To analyze Gene-based Advanced Therapy Medical Product competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene-based Advanced Therapy Medical Product market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene-based Advanced Therapy Medical Product and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene-based Advanced Therapy Medical Product.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gene-based Advanced Therapy Medical Product industry.

Chapter 3: Detailed analysis of Gene-based Advanced Therapy Medical Product company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Gene-based Advanced Therapy Medical Product in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Gene-based Advanced Therapy Medical Product in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gene-based Advanced Therapy Medical Product Industry Trends Table 2. Gene-based Advanced Therapy Medical Product Industry Drivers Table 3. Gene-based Advanced Therapy Medical Product Industry Opportunities and Challenges Table 4. Gene-based Advanced Therapy Medical Product Industry Restraints Table 5. Global Gene-based Advanced Therapy Medical Product Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gene-based Advanced Therapy Medical Product Revenue Share by Company (2021-2026) Table 7. Global Gene-based Advanced Therapy Medical Product Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Gene-based Advanced Therapy Medical Product Key Company Manufacturing Base & Headquarters Table 9. Global Gene-based Advanced Therapy Medical Product Company, Product Type & Application Table 10. Global Gene-based Advanced Therapy Medical Product Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Gene-based Advanced Therapy Medical Product by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Viral Gene Delivery System Table 15. Significant Companies of Non-viral Gene Delivery System Table 16. Global Gene-based Advanced Therapy Medical Product Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Gene-based Advanced Therapy Medical Product Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Gene-based Advanced Therapy Medical Product Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Type (2021-2026) Table 20. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Neurological Diseases Table 22. Significant Companies of Cancer Table 23. Significant Companies of Other Table 24. Global Gene-based Advanced Therapy Medical Product Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Gene-based Advanced Therapy Medical Product Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Gene-based Advanced Therapy Medical Product Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Application (2021-2026) Table 28. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Application (2027-2032) Table 29. Global Gene-based Advanced Therapy Medical Product Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Gene-based Advanced Therapy Medical Product Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Region (2021-2026) Table 32. Global Gene-based Advanced Therapy Medical Product Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Region (2027-2032) Table 34. Global Gene-based Advanced Therapy Medical Product Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Gene-based Advanced Therapy Medical Product Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Gene-based Advanced Therapy Medical Product Sales Value Market Share by Country (2021-2026) Table 37. Global Gene-based Advanced Therapy Medical Product Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Gene-based Advanced Therapy Medical Product Sales Value Market Share by Country (2027-2032) Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Novartis Gene-based Advanced Therapy Medical Product Product Portfolio Table 43. Novartis Recent Development Table 44. Amgen Company Information Table 45. Amgen Business Overview Table 46. Amgen Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Amgen Gene-based Advanced Therapy Medical Product Product Portfolio Table 48. Amgen Recent Development Table 49. Sunway Biotech Company Information Table 50. Sunway Biotech Business Overview Table 51. Sunway Biotech Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sunway Biotech Gene-based Advanced Therapy Medical Product Product Portfolio Table 53. Sunway Biotech Recent Development Table 54. Spark Therapeutics Company Information Table 55. Spark Therapeutics Business Overview Table 56. Spark Therapeutics Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Spark Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio Table 58. Spark Therapeutics Recent Development Table 59. SIBIONO Company Information Table 60. SIBIONO Business Overview Table 61. SIBIONO Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. SIBIONO Gene-based Advanced Therapy Medical Product Product Portfolio Table 63. SIBIONO Recent Development Table 64. Sarepta Therapeutics Company Information Table 65. Sarepta Therapeutics Business Overview Table 66. Sarepta Therapeutics Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sarepta Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio Table 68. Sarepta Therapeutics Recent Development Table 69. Orchard Therapeutics Company Information Table 70. Orchard Therapeutics Business Overview Table 71. Orchard Therapeutics Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Orchard Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio Table 73. Orchard Therapeutics Recent Development Table 74. Human Stem Cells Institute Company Information Table 75. Human Stem Cells Institute Business Overview Table 76. Human Stem Cells Institute Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Human Stem Cells Institute Gene-based Advanced Therapy Medical Product Product Portfolio Table 78. Human Stem Cells Institute Recent Development Table 79. Gilead Sciences Company Information Table 80. Gilead Sciences Business Overview Table 81. Gilead Sciences Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Gilead Sciences Gene-based Advanced Therapy Medical Product Product Portfolio Table 83. Gilead Sciences Recent Development Table 84. bluebird bio Company Information Table 85. bluebird bio Business Overview Table 86. bluebird bio Gene-based Advanced Therapy Medical Product Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. bluebird bio Gene-based Advanced Therapy Medical Product Product Portfolio Table 88. bluebird bio Recent Development Table 89. Biogen Company Information Table 90. Biogen Business Overview Table 91. Biogen Gene-based Advanced Therapy Medical Product Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Biogen Gene-based Advanced Therapy Medical Product Product Portfolio Table 93. Biogen Recent Development Table 94. AnGes Company Information Table 95. AnGes Business Overview Table 96. AnGes Gene-based Advanced Therapy Medical Product Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AnGes Gene-based Advanced Therapy Medical Product Product Portfolio Table 98. AnGes Recent Development Table 99. Alnylam Pharmaceuticals Company Information Table 100. Alnylam Pharmaceuticals Business Overview Table 101. Alnylam Pharmaceuticals Gene-based Advanced Therapy Medical Product Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Alnylam Pharmaceuticals Gene-based Advanced Therapy Medical Product Product Portfolio Table 103. Alnylam Pharmaceuticals Recent Development Table 104. Akcea Therapeutics Company Information Table 105. Akcea Therapeutics Business Overview Table 106. Akcea Therapeutics Gene-based Advanced Therapy Medical Product Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Akcea Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio Table 108. Akcea Therapeutics Recent Development Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Gene-based Advanced Therapy Medical Product Product Image Figure 2. Global Gene-based Advanced Therapy Medical Product Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene-based Advanced Therapy Medical Product Market Size (2021-2032) & (US$ Million) Figure 4. Global Gene-based Advanced Therapy Medical Product Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Viral Gene Delivery System Image Figure 8. Non-viral Gene Delivery System Image Figure 9. Global Gene-based Advanced Therapy Medical Product Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Gene-based Advanced Therapy Medical Product Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Type (2021-2032) Figure 12. Neurological Diseases Image Figure 13. Cancer Image Figure 14. Other Image Figure 15. Global Gene-based Advanced Therapy Medical Product Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gene-based Advanced Therapy Medical Product Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Application (2021-2032) Figure 18. Global Gene-based Advanced Therapy Medical Product Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Gene-based Advanced Therapy Medical Product Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Gene-based Advanced Therapy Medical Product Sales Value (2021-2032) & (US$ Million) Figure 21. North America Gene-based Advanced Therapy Medical Product Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Gene-based Advanced Therapy Medical Product Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Gene-based Advanced Therapy Medical Product Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Gene-based Advanced Therapy Medical Product Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Gene-based Advanced Therapy Medical Product Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Gene-based Advanced Therapy Medical Product Sales Value (2021-2032) & (US$ Million) Figure 27. South America Gene-based Advanced Therapy Medical Product Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Gene-based Advanced Therapy Medical Product Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Gene-based Advanced Therapy Medical Product Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Delivery System
  • Non-viral Gene Delivery System
Applications
  • Neurological Diseases
  • Cancer
  • Other
Companies covered
  • Novartis
  • Amgen
  • Sunway Biotech
  • Spark Therapeutics
  • SIBIONO
  • Sarepta Therapeutics
  • Orchard Therapeutics
  • Human Stem Cells Institute
  • Gilead Sciences
  • bluebird bio
  • Biogen
  • AnGes
  • Alnylam Pharmaceuticals
  • Akcea Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gene-based Advanced Therapy Medical Product Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gene-based Advanced Therapy Medical Product Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Gene-based Advanced Therapy Medical Product Market Dynamics
  1. 2.1 Gene-based Advanced Therapy Medical Product Industry Trends
  2. 2.2 Gene-based Advanced Therapy Medical Product Industry Drivers
  3. 2.3 Gene-based Advanced Therapy Medical Product Industry Opportunities and Challenges
  4. 2.4 Gene-based Advanced Therapy Medical Product Industry Restraints
3 Gene-based Advanced Therapy Medical Product Market by Company
  1. 3.1 Global Gene-based Advanced Therapy Medical Product Company Revenue Ranking in 2025
  2. 3.2 Global Gene-based Advanced Therapy Medical Product Revenue by Company (2021-2026)
  3. 3.3 Global Gene-based Advanced Therapy Medical Product Company Ranking (2024-2026)
  4. 3.4 Global Gene-based Advanced Therapy Medical Product Company Manufacturing Base and Headquarters
  5. 3.5 Global Gene-based Advanced Therapy Medical Product Company Product Type and Application
  6. 3.6 Global Gene-based Advanced Therapy Medical Product Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Gene-based Advanced Therapy Medical Product Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Gene-based Advanced Therapy Medical Product Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Gene-based Advanced Therapy Medical Product Market by Type
  1. 4.1 Gene-based Advanced Therapy Medical Product Type Introduction
  2. 4.1.1 Viral Gene Delivery System
  3. 4.1.2 Non-viral Gene Delivery System
  4. 4.2 Global Gene-based Advanced Therapy Medical Product Sales Value by Type
  5. 4.2.1 Global Gene-based Advanced Therapy Medical Product Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Gene-based Advanced Therapy Medical Product Sales Value by Type (2021-2032)
  7. 4.2.3 Global Gene-based Advanced Therapy Medical Product Sales Value Share by Type (2021-2032)
5 Gene-based Advanced Therapy Medical Product Market by Application
  1. 5.1 Gene-based Advanced Therapy Medical Product Application Introduction
  2. 5.1.1 Neurological Diseases
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global Gene-based Advanced Therapy Medical Product Sales Value by Application
  6. 5.2.1 Global Gene-based Advanced Therapy Medical Product Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gene-based Advanced Therapy Medical Product Sales Value by Application (2021-2032)
  8. 5.2.3 Global Gene-based Advanced Therapy Medical Product Sales Value Share by Application (2021-2032)
6 Gene-based Advanced Therapy Medical Product Regional Value Analysis
  1. 6.1 Global Gene-based Advanced Therapy Medical Product Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gene-based Advanced Therapy Medical Product Sales Value by Region (2021-2032)
  3. 6.2.1 Global Gene-based Advanced Therapy Medical Product Sales Value by Region: 2021-2026
  4. 6.2.2 Global Gene-based Advanced Therapy Medical Product Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gene-based Advanced Therapy Medical Product Sales Value (2021-2032)
  7. 6.3.2 North America Gene-based Advanced Therapy Medical Product Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Gene-based Advanced Therapy Medical Product Sales Value (2021-2032)
  10. 6.4.2 Europe Gene-based Advanced Therapy Medical Product Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Gene-based Advanced Therapy Medical Product Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Gene-based Advanced Therapy Medical Product Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Gene-based Advanced Therapy Medical Product Sales Value (2021-2032)
  16. 6.6.2 South America Gene-based Advanced Therapy Medical Product Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Gene-based Advanced Therapy Medical Product Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Gene-based Advanced Therapy Medical Product Sales Value Share by Country, 2025 VS 2032
7 Gene-based Advanced Therapy Medical Product Country-level Value Analysis
  1. 7.1 Global Gene-based Advanced Therapy Medical Product Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gene-based Advanced Therapy Medical Product Sales Value by Country (2021-2032)
  3. 7.2.1 Global Gene-based Advanced Therapy Medical Product Sales Value by Country (2021-2026)
  4. 7.2.2 Global Gene-based Advanced Therapy Medical Product Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Gene-based Advanced Therapy Medical Product Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Gene-based Advanced Therapy Medical Product Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Gene-based Advanced Therapy Medical Product Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Gene-based Advanced Therapy Medical Product Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Amgen
  8. 8.2.1 Amgen Company Information
  9. 8.2.2 Amgen Business Overview
  10. 8.2.3 Amgen Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Gene-based Advanced Therapy Medical Product Product Portfolio
  12. 8.2.5 Amgen Recent Developments
  13. 8.3 Sunway Biotech
  14. 8.3.1 Sunway Biotech Company Information
  15. 8.3.2 Sunway Biotech Business Overview
  16. 8.3.3 Sunway Biotech Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sunway Biotech Gene-based Advanced Therapy Medical Product Product Portfolio
  18. 8.3.5 Sunway Biotech Recent Developments
  19. 8.4 Spark Therapeutics
  20. 8.4.1 Spark Therapeutics Company Information
  21. 8.4.2 Spark Therapeutics Business Overview
  22. 8.4.3 Spark Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Spark Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio
  24. 8.4.5 Spark Therapeutics Recent Developments
  25. 8.5 SIBIONO
  26. 8.5.1 SIBIONO Company Information
  27. 8.5.2 SIBIONO Business Overview
  28. 8.5.3 SIBIONO Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  29. 8.5.4 SIBIONO Gene-based Advanced Therapy Medical Product Product Portfolio
  30. 8.5.5 SIBIONO Recent Developments
  31. 8.6 Sarepta Therapeutics
  32. 8.6.1 Sarepta Therapeutics Company Information
  33. 8.6.2 Sarepta Therapeutics Business Overview
  34. 8.6.3 Sarepta Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sarepta Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio
  36. 8.6.5 Sarepta Therapeutics Recent Developments
  37. 8.7 Orchard Therapeutics
  38. 8.7.1 Orchard Therapeutics Company Information
  39. 8.7.2 Orchard Therapeutics Business Overview
  40. 8.7.3 Orchard Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Orchard Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio
  42. 8.7.5 Orchard Therapeutics Recent Developments
  43. 8.8 Human Stem Cells Institute
  44. 8.8.1 Human Stem Cells Institute Company Information
  45. 8.8.2 Human Stem Cells Institute Business Overview
  46. 8.8.3 Human Stem Cells Institute Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Human Stem Cells Institute Gene-based Advanced Therapy Medical Product Product Portfolio
  48. 8.8.5 Human Stem Cells Institute Recent Developments
  49. 8.9 Gilead Sciences
  50. 8.9.1 Gilead Sciences Company Information
  51. 8.9.2 Gilead Sciences Business Overview
  52. 8.9.3 Gilead Sciences Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Gilead Sciences Gene-based Advanced Therapy Medical Product Product Portfolio
  54. 8.9.5 Gilead Sciences Recent Developments
  55. 8.10 bluebird bio
  56. 8.10.1 bluebird bio Company Information
  57. 8.10.2 bluebird bio Business Overview
  58. 8.10.3 bluebird bio Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  59. 8.10.4 bluebird bio Gene-based Advanced Therapy Medical Product Product Portfolio
  60. 8.10.5 bluebird bio Recent Developments
  61. 8.11 Biogen
  62. 8.11.1 Biogen Company Information
  63. 8.11.2 Biogen Business Overview
  64. 8.11.3 Biogen Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biogen Gene-based Advanced Therapy Medical Product Product Portfolio
  66. 8.11.5 Biogen Recent Developments
  67. 8.12 AnGes
  68. 8.12.1 AnGes Company Information
  69. 8.12.2 AnGes Business Overview
  70. 8.12.3 AnGes Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AnGes Gene-based Advanced Therapy Medical Product Product Portfolio
  72. 8.12.5 AnGes Recent Developments
  73. 8.13 Alnylam Pharmaceuticals
  74. 8.13.1 Alnylam Pharmaceuticals Company Information
  75. 8.13.2 Alnylam Pharmaceuticals Business Overview
  76. 8.13.3 Alnylam Pharmaceuticals Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Alnylam Pharmaceuticals Gene-based Advanced Therapy Medical Product Product Portfolio
  78. 8.13.5 Alnylam Pharmaceuticals Recent Developments
  79. 8.14 Akcea Therapeutics
  80. 8.14.1 Akcea Therapeutics Company Information
  81. 8.14.2 Akcea Therapeutics Business Overview
  82. 8.14.3 Akcea Therapeutics Gene-based Advanced Therapy Medical Product Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Akcea Therapeutics Gene-based Advanced Therapy Medical Product Product Portfolio
  84. 8.14.5 Akcea Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst